Debanjana Chatterjee, an analyst from JonesTrading, reiterated the Buy rating on Pharvaris. The associated price target remains the same with $43.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee has given his Buy rating due to a combination of factors including the promising progress of Pharvaris’s clinical trials and its strong financial position. The company’s RAPIDe-3 trial for IR deucrictibant, aimed at treating hereditary angioedema (HAE), is on schedule to deliver key data by the end of 2025, which is anticipated to positively impact the stock. Additionally, the ongoing Ph3 CHAPTER-3 prophylaxis study is advancing as expected, with results projected for the second half of 2026.
Furthermore, the initiation of the Ph3 CREAATE study for deucrictibant as both a prophylactic and on-demand treatment for AAE-C1INH attacks demonstrates the company’s commitment to expanding its treatment portfolio. The financial health of Pharvaris is robust, with a substantial cash reserve of €329 million, ensuring operational stability well into the first half of 2027. These elements collectively underpin Chatterjee’s confidence in the stock’s potential, leading to the Buy rating.
Chatterjee covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Opus Genetics, and KalVista Pharmaceuticals. According to TipRanks, Chatterjee has an average return of 31.8% and a 64.13% success rate on recommended stocks.
In another report released on November 14, Morgan Stanley also maintained a Buy rating on the stock with a $37.00 price target.